We provide you with 20 years of free, institutional-grade data for CGEM stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CGEM. Explore the full financial landscape of CGEM stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2017-12-21 | 1423417 | CGEM | 10-K | Url |
| 2017-10-17 | 1423417 | CGEM | 10-Q | Url |
| 2017-10-17 | 1423417 | CGEM | 10-Q | Url |
| 2017-10-17 | 1423417 | CGEM | 10-Q | Url |
| 2017-09-26 | 1423417 | CGEM | 10-K | Url |
| 2017-09-20 | 1423417 | CGEM | 10-Q | Url |
| 2016-10-19 | 1423417 | CGEM | 10-Q | Url |
| 2015-06-11 | 1423417 | CGEM | 10-K | Url |
| 2015-06-11 | 1423417 | CGEM | 10-Q | Url |
| 2014-11-14 | 1423417 | CGEM | 10-Q | Url |
| 2014-08-21 | 1423417 | CGEM | 10-Q | Url |
| 2014-05-15 | 1423417 | CGEM | 10-Q | Url |
| 2014-03-31 | 1423417 | CGEM | 10-K | Url |
| 2013-11-14 | 1423417 | CGEM | 10-Q | Url |
| 2013-08-14 | 1423417 | CGEM | 10-Q | Url |
| 2013-05-09 | 1423417 | CGEM | 10-Q | Url |
| 2013-03-28 | 1423417 | CGEM | 10-K | Url |
| 2012-11-14 | 1423417 | CGEM | 10-Q | Url |
| 2012-08-10 | 1423417 | CGEM | 10-Q | Url |
| 2012-05-15 | 1423417 | CGEM | 10-Q | Url |
| 2012-03-28 | 1423417 | CGEM | 10-K | Url |
| 2011-11-14 | 1423417 | CGEM | 10-Q | Url |
| 2011-08-12 | 1423417 | CGEM | 10-Q | Url |
| 2011-05-11 | 1423417 | CGEM | 10-Q | Url |
| 2011-03-30 | 1423417 | CGEM | 10-K | Url |
| 2010-11-15 | 1423417 | CGEM | 10-Q | Url |
| 2010-08-13 | 1423417 | CGEM | 10-Q | Url |
| 2010-05-14 | 1423417 | CGEM | 10-Q | Url |
| 2010-03-26 | 1423417 | CGEM | 10-K | Url |
| 2009-11-16 | 1423417 | CGEM | 10-Q | Url |
| 2009-08-07 | 1423417 | CGEM | 10-Q | Url |
| 2009-05-08 | 1423417 | CGEM | 10-Q | Url |
| 2009-03-24 | 1423417 | CGEM | 10-K | Url |
| 2008-10-15 | 1423417 | CGEM | 10-Q | Url |
| 2008-07-14 | 1423417 | CGEM | 10-Q | Url |
Cullinan Oncology, Inc(NASDAQ:CGEM) 
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalati...
Website: https://www.cullinanoncology.com/
Founded: 2016
CEO: Owen Hughes
Sector: Pharmaceuticals
Industry:
Share this website to your friends
The information provided in this report about CGEM stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.